Enigma Biomedical USA Unveils Elite Scientific Advisory Board

In a groundbreaking announcement, Enigma Biomedical USA (EB USA), based in Knoxville, Tennessee, has officially formed a Scientific Advisory Board (SAB) that promises to revolutionize the understanding and treatment of neurodegenerative diseases, including Alzheimer's Disease. This distinguished team is composed of some of the brightest minds from across the globe, spanning various fields such as chemistry, biology, and medicine.

Leadership of the Scientific Advisory Board

Leading the SAB is Professor Serge Gauthier, an acclaimed expert from McGill University in Montreal, Quebec. Under his leadership, the board includes an impressive lineup of professionals:

- **Richard Hargreaves, Ph.D.** - Senior Vice President and Head of Neuroscience at Bristol Myers Squibb, NJ.

- **Kenji Ishii, M.D.** - Team Leader for Neuroimaging Research at the Tokyo Metropolitan Institute of Gerontology, Japan.

- **Keith Johnson, M.D., Ph.D.** - Director of Molecular Neuroimaging at Massachusetts General Hospital and a professor at Harvard Medical School, MA.

- **Sterling Johnson, Ph.D.** - Jean R. Finley Professor of Geriatrics and Dementia at the University of Wisconsin, specializing in Alzheimer's prevention.

- **Eric M. Reiman, M.D.** - Executive Director of the Banner Alzheimer’s Institute and a leading researcher at the University of Arizona.

- **Christopher Rowe, FRACP, M.D.** - Head of Molecular Imaging Research at the Austin Hospital in Australia.

- **Koen Van Laere, M.D., Ph.D., D.Sc.** - Head of Nuclear Medicine and Molecular Imaging at University Hospital Leuven, Belgium.

- **Henrik Zetterberg, M.D., Ph.D.** - A prominent figure in neuroscience from the University of Gothenburg and University College London.

Insights from the Leaders

Professor Gauthier expressed his enthusiasm for the assembly of such a talented group, stating, “We are thrilled to collaborate with such accomplished professionals. This blend of basic science and clinical expertise is crucial for accelerating the development of treatments that can profoundly impact the lives of those affected by neurodegenerative conditions.”

Rick Hiatt, President and CEO of EB USA, emphasized the significance of this collaboration, indicating it could lead to major advancements in understanding and addressing the unmet needs within neurodegenerative disease research. “With the commitment of these world-class researchers, we believe our mission to develop disease-modifying therapies will make significant progress,” he added.

Aiming for Breakthroughs in Neurological Biomarkers

Enigma Biomedical USA aims to become the leading provider of imaging biomarkers specifically for neurological pathologies. Their groundbreaking neuroimaging biomarkers, including advanced Tau and Amyloid PET imaging tools, are designed to foster innovative research that paves the way toward effective therapies. Recently, EB secured a valuable partnership with AbbVie to explore new 4R Tau PET imaging biomarkers.

Looking Ahead

With the establishment of this SAB, Enigma Biomedical USA is poised to make significant strides in the complex landscape of neurodegenerative diseases. Their innovative strategies may soon offer new hope to millions affected by these challenging conditions.

Stay tuned as we follow their progress towards potentially revolutionary developments in treatment!